Enovis (NYSE:ENOV) Rating Increased to Hold at Zacks Research

Enovis (NYSE:ENOV) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on ENOV. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. BMO Capital Markets began coverage on Enovis in a research report on Wednesday, July 8th. They set an “outperform” rating and a $29.00 target price on the stock. Evercore set a $32.00 target price on Enovis in a research report on Monday, July 6th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Finally, William Blair initiated coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.86.

Enovis Trading Down 3.1%

NYSE:ENOV opened at $29.32 on Wednesday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -1.47 and a beta of 1.39. Enovis has a 52 week low of $19.14 and a 52 week high of $34.28. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The firm has a 50 day moving average of $23.96 and a 200 day moving average of $23.78.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts anticipate that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 4,200 shares of company stock valued at $92,084 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enovis

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System lifted its holdings in Enovis by 1.2% in the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after acquiring an additional 621 shares during the period. MGO One Seven LLC grew its stake in shares of Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after purchasing an additional 650 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Empowered Funds LLC grew its stake in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the period. Finally, Inscription Capital LLC increased its holdings in shares of Enovis by 9.4% during the 4th quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after purchasing an additional 1,016 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.